Innoviva Inc
Change company Symbol lookup
Select an option...
INVA Innoviva Inc
UBQU Ubiquitech Software Corp
VZ Verizon Communications Inc
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Price
Delayed
$16.66
Day's Change
-0.019 (-0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
16.94
Day's Low
16.66
Volume
(Light)

Today's volume of 164,643 shares is on pace to be much lighter than INVA's 10-day average volume of 643,002 shares.

164,643

Display:

Providers:

UpdateCancel
6 providers
October 27, 2021
Innoviva Reports Third Quarter 2021 Financial Results

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the third quarter ended September 30, 2021. Gross royalty revenues of $101.3 million from Glaxo Group Limited ("GSK") for the third quarter of 2021...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.